Meditation Contraindications and Risks: When to Use Caution

Meditation carries a reputation so uniformly positive that the rare but real risks attached to it often get quietly set aside. This page examines the clinical and psychological contraindications, the mechanisms that can make meditation destabilizing for specific populations, and the classification frameworks researchers use to separate ordinary discomfort from genuine adverse effects. The goal is a clear-eyed reference — neither alarmist nor dismissive.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Checklist or steps (non-advisory)
• Reference table or matrix

Definition and scope

A contraindication, in clinical language, is a condition or factor that makes a particular intervention inadvisable. For meditation, the term applies across a spectrum — from hard contraindications where a practice poses documented psychological risk, to relative contraindications where the intervention may proceed with modification, monitoring, or professional support.

The scope is broader than most practitioners expect. A landmark 2022 study published in Acta Psychiatrica Scandinavica by Schlosser, Jones, and colleagues found that approximately 25% of regular meditators reported at least one adverse effect they attributed to practice — ranging from heightened anxiety to perceptual disturbances and depersonalization. That figure is not a reason to avoid meditation; it is a reason to understand it more precisely.

The broader landscape of meditation practice spans dozens of distinct techniques — breath-focused, mantra-based, open awareness, visualization — and the risk profile is not uniform across them. Intensive silent retreat formats produce adverse event rates substantially higher than brief, guided, app-based sessions, a distinction that classification frameworks must account for.

Core mechanics or structure

Meditation produces measurable changes in nervous system tone, attention regulation, and interoceptive awareness (the brain's monitoring of internal body states). These same mechanisms that make it therapeutic are the ones that can, in specific contexts, become destabilizing.

Three physiological and psychological pathways are most implicated in adverse effects:

Parasympathetic activation without adequate regulatory capacity. Most meditation techniques shift the autonomic nervous system toward parasympathetic dominance — slower heart rate, reduced cortisol output. For individuals with dysregulated vagal tone or a history of freeze-state trauma responses, deep parasympathetic induction can trigger dissociation rather than relaxation.

Interoceptive amplification. Practices that direct sustained attention inward — body scan meditation being the clearest example — increase sensitivity to bodily sensations. For individuals with somatic anxiety, health anxiety, or panic disorder, this amplification can feed rather than quiet distress.

Ego boundary softening. Certain concentration-heavy and open-awareness practices can destabilize the ordinary sense of self-continuity. Clinicians working with individuals who have thin psychological boundaries, active psychotic symptoms, or borderline personality features report this as the most concerning mechanism, because the dissolution of ordinary self-referential processing is a therapeutic goal in some traditions but a symptom in others.

Causal relationships or drivers

The relationship between meditation and adverse effects is not random — specific variables reliably predict higher risk.

Dose and intensity. The Varieties of Contemplative Experience project at Brown University, led by Willoughby Britton, documented adverse effects across a sample of 100 meditators, including 73 who had completed intensive retreat settings. Duration of daily practice, retreat format, and depth of absorption states were all positively associated with adverse event frequency.

Trauma history. Individuals with post-traumatic stress disorder face a specific risk profile when beginning meditation without trauma-informed support. The inward attention that meditation cultivates can surface traumatic memories before a person has the regulatory skills to process them. The clinical literature on meditation for trauma and PTSD consistently recommends titrated, trauma-sensitive approaches rather than standard protocols for this population.

Pre-existing psychiatric conditions. Bipolar I and II disorder, schizophrenia spectrum conditions, active substance use disorders, and severe depressive episodes with psychotic features are all associated with elevated risk. Meditation does not cause these conditions, but it can interact with them in ways that destabilize symptom management.

Teacher quality and setting. A significant portion of adverse events in the literature occurred in settings where practitioners lacked clinical training and were therefore unable to recognize or respond to psychological distress as it emerged.

Classification boundaries

Not every difficult meditation experience qualifies as an adverse event. Researchers have worked to establish meaningful boundaries.

The Cheetah House adverse effects framework, developed by researchers associated with Britton's lab, distinguishes between:

• Expected challenges — temporary difficulty concentrating, mild restlessness, brief emotional release
• Adverse meditation experiences — persistent unwanted changes to perception, cognition, mood, or behavior lasting more than a few days
• Clinically significant adverse events — experiences requiring professional mental health intervention, hospitalization, or that cause significant functional impairment

A parallel distinction applies by practice type. Mindfulness meditation, particularly Mindfulness-Based Stress Reduction (MBSR) as standardized by the University of Massachusetts Medical School's Center for Mindfulness, includes explicit screening protocols and teaches instructors to recognize when participants need referral. Less structured commercial or self-directed formats typically lack these safeguards.

The conceptual overview of how wellness practices work provides useful framing for understanding why context and structure affect outcome — a reminder that no intervention exists in isolation from the conditions in which it is delivered.

Tradeoffs and tensions

The central tension in this literature is between two legitimate concerns: overmedicalizing a practice with genuine population-level benefit, and under-warning individuals who face real risk.

Meditation-Based Cognitive Therapy (MBCT) has robust evidence for reducing depressive relapse — a 2016 meta-analysis in JAMA Internal Medicine (Goyal et al.) found mindfulness meditation programs produced moderate improvements in anxiety, depression, and pain. The evidence base is real. But the same inward attention that helps someone with recurrent mild depression notice and interrupt rumination can, in someone with active psychosis or severe trauma, accelerate dysregulation.

A second tension involves the commercialization of wellness. The meditation app industry reached an estimated $2.08 billion in global revenue in 2022 (Grand View Research market report), and the economic incentives favor broad accessibility messaging over nuanced risk communication. Apps rarely include intake screening questions about psychiatric history, and their instructions typically do not distinguish between users who would benefit from standard protocols and those who need modified approaches.

Common misconceptions

Misconception: meditation is always calming.
The neurological reality is more complicated. Practices that involve sustained concentration can increase cortical arousal in some individuals. Depersonalization, emotional flooding, and paradoxical anxiety are documented — not rare — responses, particularly in high-dose or retreat contexts.

Misconception: adverse effects are a sign the practice is "working."
Some traditions frame psychological difficulty during meditation as productive transformation. This framing is not clinically supported as a universal principle. Persistent perceptual disturbances, derealization lasting weeks, or significant functional decline are not milestones — they are signals warranting clinical evaluation.

Misconception: mindfulness is safe for everyone with depression.
MBCT is explicitly contraindicated for individuals in an acute depressive episode (Beck Depression Inventory score above 29, per MBCT protocol guidelines). It is designed for people in remission from recurrent depression, not for those in active crisis. This distinction matters enormously and is frequently lost in popular coverage.

Misconception: shorter sessions carry no risk.
Duration is one variable, not the only one. The nature of the technique, the practitioner's history, and the presence or absence of support are equally significant. A 10-minute body scan can be more activating for a trauma survivor than a 45-minute breath-awareness session.

Checklist or steps (non-advisory)

Factors clinicians and informed practitioners typically review before recommending or beginning a meditation practice:

1. Psychiatric history — presence of schizophrenia spectrum, bipolar disorder, active psychosis, or recent psychiatric hospitalization
2. Trauma history — past or current PTSD, complex trauma, or dissociative symptoms
3. Current symptom stability — whether depression, anxiety, or other conditions are in a stable phase versus active escalation
4. Medication considerations — some psychotropic medications alter sensory perception and may interact unpredictably with altered-state practices
5. Practice format — distinguishing between brief guided sessions, self-directed daily practice, and multi-day intensive retreats
6. Support availability — whether a qualified teacher, therapist, or clinician familiar with meditation's psychological effects is accessible
7. Technique selection — matching technique to individual profile (e.g., movement-based or eyes-open practices for individuals with dissociation risk; breath awareness rather than body scan for somatic anxiety)
8. Monitoring plan — whether there is a structured way to track and respond to emerging adverse effects over time

Reference table or matrix